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Background: Thyrotoxicosis is a cause of secondary osteoporosis. High concentrations of triiodotironine (T3) in
Graves’ disease stimulate bone turnover, but it is unclear if euthyroidism will always normalize bone metabolism.
Thyrotropin (TSH) is known to affect directly the bone metabolism through the TSH receptor and TSH receptor
antibodies (TRAb) may have an important role in bone turn-over.
The aim of our study was to determine, in pre and postmenopausal euthyroidism patients with previous overt
hyperthyroidism due to Graves’ disease the bone mineral density (BMD) as well as factors that could affect BMD in
each group, including TRAb.
Methods: Cross-sectional, non-interventional study. Fifty-seven patients with previous hyperthyroidism due to Graves’
disease (premenopausal: 30, postmenopausal: 27) that remained euthyroid for at least 6 months prior to study were
included and compared with fifty- two matched respective controls. Thyrotoxine (T4), TSH, TRAb and BMD were measured.
Results: Only euthyroid postmenopausal patients with a history of hyperthyroidism due to Graves’ disease showed lower
whole body BMD than matched controls. The BMD expressed as Z-score was less in whole body and lumbar spine in
postmenopausal in relation to premenopausal women with previous overt hyperthyroidism due to Graves’ disease.
In the postmenopausal patients, the Z-score of lumbar spine BMD correlated negatively with TRAb (r = −0,53, p < 0.008),
positively with the time of evolution of the disease (r = +0.42, p < 0.032) and positively with the time of euthyroidism
(r = + 0.50, p < 0.008), but neither with serum T4 nor TSH. In a multiple regression analysis TRAb was the only significant
independent variable in relation to lumbar spine BMD (F = 3. 90, p < 0.01).
Conclusions: In euthyroid women with a history of Graves’ hyperthyroidism, BMD was only affected in the
postmenopausal group. The negative correlation of Z-score of lumbar spine BMD with TRAb suggests that this antibody
may affect the bone metabolism.Introduction
Thyroid hormones exert their effect on osteoblasts via
nuclear receptors stimulating osteoclastic bone resorp-
tion [1-3]. Hyperthyroidism is thus one of the major
causes of secondary osteoporosis.
Reduction in bone mineral density (BMD) following
hyperthyroidism in female subjects has been described
in many reports [4-10]. A bone histomorphometric* Correspondence: aoyacobi@intramed.net
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reproduction in any medium, provided the orstudy in patients with hyperthyroidism has shown that
the increase in osteoclastic resorption was more promin-
ent in cortical than in cancellous bone [9,11] and that
normalization of thyroid function was associated with an
increase in lumbar spine BMD, which was preceded by a
significant attenuation of bone turnover [12]. However,
discrepancy exists in the results of studies to determine
whether antithyroid treatment can completely normalize
bone metabolism [13,14]. In those studies, the time of
follow up varied considerably, the populations were het-
erogeneous with reference to etiology of hyper-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Furthermore, it has recently been demonstrated that
TSH affects bone metabolism through the TSH receptor
found on osteoblast and osteoclast precursors in mice
[15]. On the other hand, both higher serum TSH recep-
tor antibodies (TRAb) and thyroid stimulating anti-
bodies had a significant correlation with a reduction in
BMD at the distal radius in male patients with untreated
Graves’disease. In addition, higher TSAb significantly
correlated with higher urinary N-terminal telopeptide of
type I collagen [16].
Previous studies have suggested that the past history
of Graves’ disease itself, and not the current state of thy-
roid function, was responsible for bone loss in women
receiving long-term levothyroxine therapy [17]. These
results suggested some deleterious effects of TRAb and
TSAb on bone metabolism, probably via TSH receptors
on osteoblasts or osteoclasts.
The aim of our study was to determine BMD in pre
and postmenopausal euthyroid female patients with pre-
vious overt hyperthyroidism due to Graves’ disease as




One hundred and twenty-two patients with personal his-
tory of Graves’ disease and euthyroidism attended con-
secutively in our endocrine Division between 2006 and
2008 were evaluated. Fifty seven patients who fulfilled
the inclusion criteria were consecutively enrolled in this
study after informed consent. The study was carried out
in compliance with the Helsinki Declaration. Sixty five pa-
tients were excluded by previous bone fracture (n = 3);
non-thyroidal illness (n = 16); intake of drugs that could
influence bone metabolism (n = 18); incomplete follow up
(n = 21); early menopause (n = 1) and refused to partici-
pate (n = 6).
Inclusion criteria were: personal history of Graves’ dis-
ease and persistent euthyroidism for at least 6 months
before entering the study. Exclusion criteria were: per-
sonal history of fracture prior to the beginning to the
disease, non-thyroidal illness (liver disease, renal dys-
function, malignancy, diabetes mellitus, hyperparathyr-
oidism, hypercortisolism, or hypogonadism) or intake of
drugs (active vitamin D3, bisphosphonates, calcitonin,
testosterones, steroids, diuretics, heparin, or anticonvul-
sants) that could influence bone metabolism and early
menopause. All subjects underwent plain x-ray (antero-
posterior and lateral views) of the lumbar spine, and
those found to have scoliosis, compression fractures, or
ectopic calcifications that could interfere with the bone
mineral results were also excluded.The diagnosis of Graves’ disease had been established
by the presence of symptoms and signs of hyperthyroid-
ism, diffuse goitre, ophthalmopathy and/or positive
TRAb, high serum concentrations of thyroxine (T4) and
triiodothyronine (T3) and suppressed TSH. Ultimate
treatment was achieved with antithyroid drugs in five
patients and radioiodine in fifty-two patients. All pa-
tients had at least two T4 and TSH values within the
normal range for at least 6 months prior to this study.
The patients were divided into two groups according
to their menopausal status at the moment of the study
(Premenopausal n = 30 and Postmenopausal n = 27) and
were compared with 52 euthyroid controls mathed
according to age, gender, and anthropometrical status
(Premenopausal controls n = 36 and Postmenopausal
controls n = 16). Menopause was defined as one year of
amenorrhea and high levels of FSH.
All subjects completed a questionnaire administered
by the physician or nurse and underwent laboratory
blood tests. The questionnaire determined risk factors of
osteoporosis, calcium intake and score of activity (0 =
immobile, 1 = normal daily activity, 2 = programmed
physical activity 2 times per week, 3 = programmed
physical activity 3 times per week and 4 = programmed
physical activity > three times per week.
Total time of hyperthyroidism was calculated as the
sum of all the periods in which the patient had high
levels of thyroid hormones and suppressed TSH (includ-
ing relapses). Time of euthyroidism was considered since
the moment the patient permanently normalized T4 and
TSH levels postreatment until inclusion in the study.
The total time of evolution of the disease includes the
sum of both periods: hyperthyroidism and euthyroidism.
Biochemical measurements
Blood samples were drawn after an overnight fast in all
the patients and matched controls of this study. The thy-
roid function variables: T4 and TSH were measured
using commercially available kits (Solid phase competi-
tive chemiluminescent enzyme inmumoasay-Immulite
2000, interassay coefficient of variation (CV): 10% and
5% respectively). TRAb was measured by radioreceptor
assay [18] using a commercial kit (Radioreceptor assay;
this method is based on the ability of TRAb to inhibit
the binding of 125 I b-TSH to detergent-solubilized
TSH-receptors from porcine thyroids cells. Results are
expressed as the percentage of inhibition of 125I b-TSH
binding, interassay CV: 10%). Control values were (mean
+/− SD) 2.4+/−6.1% and results higher than 14.6% were
considered positive [18-20]. Briefly, total calcium, phos-
phorus and creatinine were measured in serum using
standard laboratory methods. Serum intact parathyroid
hormone was measured by an Immulite 1000 with intra-
and interassay CVs of 5.5% and 7.9%, respectively. Serum
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DiaSorin RIA with inter- and intra-assay CVs 12,8% and
8,4%, respectively.
BMD measurements
BMD measurements were performed at the Lumbar
spine (L2-L4), hip and whole body by dual energy X-ray
absorptiometry (DPX-L; Lunar, Madison, WI). Values of
BMD were expressed as the mean in g/cm2 and Z-
scores on the basis of normal reference values of an age
and gender-matched group provided by the DXA system
manufacturer. The same operator measured all the sub-
jects. The phantom precision expressed as the CV (%)
was 0.82.
Statistical analysis
Results are expressed as percentage, mean ± SD when
data passed a normality test of Kolmogorov-Smirnov or
median and range when they did not. Differences be-
tween groups were analyzed using the Student T-test
(when the distribution was normal) or Mann–Whitney’s
U test for assessment of non-parametric median values.
Correlation coefficients and multiple regression analyses
were calculated. A p-value <0.05 was considered statisti-
cally significant. Statistical analysis was performed with
the GraphPad Instat software program and SPSS 17.0.
Advanced Calculus. Statistical Software. SPSS Inc,
Chicago. 2008.
A post hoc study was applied in order to evaluate the
power calculation with a 0.5 difference between the
Z- score medians.
Results
The euthyroid patients with a history of hyperthyroidism
due to Graves’ disease did not differ in relation to their
respective controls in demographic and anthropometric
characteristics, osteoporosis risk factors nor in biochem-
ical data (Table 1). The euthyroid patients with a history
of hyperthyroidism due to Graves’ disease evaluated in
premenopause presented BMD similar to their respect-
ive controls in all the regions studied and postmeno-
pausal women only presented a lower whole body BMD
than controls (Table 1). Furthermore, both whole body
and lumbar spine BMD Z-scores were significantly lower
in postmenopausal compared to premenopausal women
(Figure 1).
In order to investigate which variable could account
for the smaller BMD expressed as Z-score in posme-
nopausal patients in relation to the premenopausal
ones, both groups with previous hyperthyroidism due to
Graves’ disease were compared. No significant differ-
ences were found in osteoporosis risk factors nor in
biochemical data of mineral metabolism. Calcium in-
take was higher in the postmenopausal than in thepremenopausal group (p < 0.003). The posmenopausal
euthyroid Graves’ disease patients presented the begin-
ning of their disease at an older age, had a longer time
of evolution of the disease, a longer time of euthyroidism
and a higher percentage of patients with L-T4 treatment
than the premenopausal group. No differences were
found in the levels of T4, TSH, TRAb or the percentage
of patients with persistently positive TRAb at the time of
the study (Table 2). In the premenopausal group, no cor-
relation was found between the Z-score of L2-L4 with
time of evolution of the disease, time of euthyroidism, nor
with TRAb at the moment of study. However, in the
posmenopausal group, the Z-score of lumbar spine corre-
lated negatively with TRAb (r = −0,53, p <0.008) and posi-
tively with time of evolution of the disease (r = +0.42,
p < 0.032) and with time of euthyroidism (r = 0.50,
p < 0.008) (Figures 2 and 3). On the other hand, TRAb
correlated negatively with the time of evolution of the dis-
ease (r = −0.45, p <0.02) (Figure 4). There was no correl-
ation between BMD and T4 or TSH (r = +0.14 and −0.19
respectively, p:.ns). In the multiple regression analysis
using the Z-Score of BMD in L2-L4 as the dependent vari-
able and TRAb, T4, TSH and time of evolution of the dis-
ease as independent variables, the TRAb was the only
significant variable in relation to L2L4 BMD, accounting
for 45.2% of the variation in L2L4 BMD (F = 3,90, p <0.01).
Discussion
Hyperthyroidism has been shown to accelerate bone
turnover [11] and shorten the normal bone remodelling
cycle [21]. Thus, active thyrotoxicosis resulted in a 12–
15% reduction of BMD, predominantly in cortical bone
[22]. Several small studies have been devised to assess
the change in bone mass after treatment of hyperthy-
roidism. Although all of these studies have demonstrated
improvement in bone density after restoration of the eu-
thyroid state, the amount of improvement and the time
frame evaluated varied considerably, the populations
studied on the different surveys were heterogeneous
with reference to etiology of hyperthyroidism, osteopor-
osis risk factors and menopausal status [23-27]. The
long-term effects of treated thyrotoxicosis remain uncer-
tain, but most studies suggest a persistent two to three-
fold increased relative risk for hip fracture, mainly in
postmenopausal women [28-32].
In the present study only women with previous
Graves’ disease hyperthyroidism were investigated, and
they were analyzed in two groups according to the
menopausal status at the time of evaluation. It was dem-
onstrated that the population of premenopausal patients
with a previous history of hyperthyroidism due to
Graves’ disease and long time of euthyroidism, showed
no differences in BMD in relation to their matched con-
trols; while postmenopausal patients at the time of
Table 1 Data of pre and post-menopausal patients with history of hyperthyroidism by Graves’ disease
GD-Pre-MP (n = 30) C-Pre-MP (n = 36) p GD-Pos-MP (n = 27) C-Pos-MP (n = 16) p
Age (years) 38,8 ± 9,7 36,3 ± 10,6 ns 56,6 ± 5,5 54,8 ± 7,4 ns
Age of menarche (years) 12,7 ± 1,1 12,6 + 1,2 ns 12,9 + 0,6 12,8 + 0,9 ns
Age of menopausal (years) - - ns 47,6 ± 4,6 47,5 ± 4,7 ns
BMI 25,2 ± 3,8 23,2 ± 4,2 ns 26,1 ± 4,5 28,6 ± 4,7 ns
Maternal hip fracture (%) 0 0 ns 0 0 ns
Fracture (%) 0 0 ns 1 (4) 0 ns
Tobacco (%) 3 (10) 4 (11) ns 2 (7,4) 4 (25) ns
Alcohol (%) 0 0 ns 0 0 ns
Physical activity 1,3 ± 0,6 1,1 ± 0,5 ns 1,3 + 0,7 1,2 ± 0,5 ns
Calcium intake (gr/day) 240 (23–1113) 416 (117–1277) ns 795 (194–1562) 280 (51–886) <0.003
Serum calcium (mg/dL) 9.4 ± 0.5 9.4 ± 0.4 ns 9.4 ± 0.4 9.4 ± 0.4 ns
Serum phosphorous (mg/dL) 3.4 ± 0.6 3.7 ± 0.6 ns 4.0 ± 0.5 4.0 ± 0.5 ns
Serum creatinine (mg/dL) 0.7 ± 0.1 0.8 ± 0.1 ns 0.7 + 0.1 0.8 + 0.1 ns
PTH (ug/mL) 59.8 ± 30.7 45.9 ± 15.8 ns 48.3 ± 17.9 62.8 ± 24.2 ns
25OHD (ng/mL) 26,7 ± 11,5 50,3 ± 20,5 ns 29,7 ± 17,2 37,1 ± 12,4 ns
BMD L2-L4 (gr/cm2) 1,19 ± 0,15 1,17 ± 0,12 ns 1,001 ± 0,17 1,06 ± 0,13 ns
BMD L2-L4 (z-score) 0,11 ± 1,19 0,04 ± −1,0 ns −0,43 ± 1,17 −0,51 ± 0,83 ns
BMD FN (gr/cm2) 0,96 ± 0,10 0,95 ± 0,12 ns 0,852 ± 0,14 0,84 ± 0,13 ns
BMD FN (z-score) 0,11 ± 0,8 0,00 ± 0,89 ns −0,04 ± 0,87 −0,53 ± 0,81 ns
BMD W-B (gr/cm2) 1,13 ± 0,08 1,15 ± 0,06 ns 0,99 ± 0,14 1,12 ± 0,10 <0,003
BMD W-B (z-score) 0,24 ± 0,91 0,61 ± 0,74 ns −0,79 + 1,03 0,40 ± 0,90 <0,0007
Data are presented as means ± SD, median or percentages. The power calculation with a 0.5 difference between the Z- score medians for Lumbar spine (L2-L4),
femoral neck (FN) and whole body (W-B) were between 0.32 and 0.58. GD-Pre-MP Premenopausal Graves Disease, GD-Post-MP Postmenopausal Graves Disease,
C-Pre-MP Premenopausal controls, C-Pos-MP Post-menopausal controls.
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tion to their matched controls. Whole body BMD repre-
sents predominantly cortical bone, and it is known that
thyroid hormone excess causes mainly cortical bone loss
[22]. This was in keeping with results obtained in hyper-
thyroid patients of non-autoimmune origin such as
multinodular goitre [33]. Since only three patients wereFigure 1 Bone mineral density expressed as Z-score in W-B, FN
and L2-L4 in premenopausal (n = 30) vs postmenopausal patients
(n = 27) with a history of hyperthyroidism due to Graves’ disease.
*: p < 0,005, **: p < 0,0002. W-B: whole body; FN: femoral neck; L2-L4:
lumbar spine; Pre-MP: premenopausal; Post-MP: postmenopausal.excluded for prior fractures, it is improvable that exclu-
sion of patients with more severe bone disease may have
resulted in a bias of this study.
When comparing the euthyroid postmenopausal to eu-
thyroid premenopausal Graves’ disease patients, not only
did they have a lower whole body BMD Z-score but also
a lower lumbar spine BMD Z-score.. The BMD differ-
ence between pre- and postmenopausal patients at the
time of evaluation with a previous history of hyperthy-
roidism due to Graves’ disease is remarkable. This differ-
ence cannot be due to posmenopausal status per se,
since it was avoided using Z score (on the basis of nor-
mal reference values of an age- and gender-matched
group provided by the DXA system manufacturer), or to
the duration of hyperthyroidism which was similar in
both groups, or to the time of euthyroidism which was
even longer in the posmenopausal group. T4, TSH and
TRAb values were similar at the time of evaluation in both
groups. Despite the fact that the inclusion criteria of per-
sistent euthyroidism for 6 months or more before entering
the study may have introduced a bias due to the short
time interval for re-establishing normal BMD-levels,
medium time of persistent euthyroidism was 70.6 and
146.8 months for pre and posmenopausal respectively.
Table 2 Graves’ disease characteristics in euthyroid premenopausal vs postmenopausal patients
G-Pre-MP (n = 30) G-Pos-MP (n = 27) p
Age of beginning of the disease (years) 30.0 ± 7.7 40.9 ± 11.0 0,0007
Time of hyperthyroidism (months) 38,5 ± 44,9 53,7 ± 88,0 ns
Time of euthyroidism (months) 70,6 ± 68,2 146,8 ± 126,9 0,007
Time of evolution of disease (months) 98,8 ± 80,5 198,9 ± 130,0 0,002
Euthyroid patients with T4 (%) 60 93 0,003
T4 (ug/dL) 9,2 ± 2,2 9,8 ± 1,8 ns
TSH (uUI/mL) 1,4 ± 1,4 1,6 ± 1.3 ns
TRAb (%) 22,4 ± 19,0 21,5 ± 21,7 ns
PositiveTRAb patients (%) 45 34 ns
Data are presented as means ± SD, median or percentages. GD-Pre-MP Premenopausal Graves Disease, GD-Post-MP Postmenopausal Graves Disease.
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ten-year later onset of hyperthyroidism in the postmeno-
pausal group compared to the premenopausal group at
the moment of the evaluation, the former starting during
their perimenopause. This would reaffirm that the begin-
ning of hyperthyroidism during this period of great vul-
nerability of bone mass [34] has a more deleterious
effect on bone or does not allow a complete recovery
of BMD.
This study shows that postmenopausal patients at the
time of evaluation with a previous history of perimeno-
pausal hyperthyroidism due Graves’ disease, despite a
long time of euthyroidism, had a lower bone mass than
matched controls. In contrast, those patients studied in
premenopause with a previous history of hyperthyroid-
ism due Graves’ disease did not show any difference
from matched controls.
In the correlation analyses, only the postmenopausal
population showed an inverse correlation between L2-L4
Z-score and the level of TRAb as well as a positive cor-
relation with the time of evolution of the disease and
time of euthyroidism. On the other hand, as expected,
TRAb and time of evolution of the disease showed a
negative correlation. So with longer time of evolution ofFigure 2 Negative correlation between bone mineral density Z-
score of L2-L4 and TRAb in postmenopausal patients with
Graves’ disease (n = 27). (R = −0, 3, p < 0,008).the disease, lower TRAb levels and better BMD were
seen. TRAb was the only significant variable in relation
to lumbar spine BMD in the multiple regression analysis.
This result suggested a deleterious effect of TRAb on
bone metabolism. To our knowledge, only a few studies
conducted to date have suggested an effect of TRAb on
BMD in patients with Graves’ disease [16,35]. To our
knowledge, no similar analyses were performed in
women with a history of toxic multinodular goitre, i.e.
subjects negative for TRAb.
A recent study on TSH receptor in null mice found
evidence for direct effects of TSH on osteoblastic bone
formation and osteoclastic bone resorption, mediated by
the receptor on osteoblast and osteoclast precursors.
These animals were found to be osteoporotic despite
thyroid extract replacement therapy, linking directly the
bone phenotype to the lack of action of TSH on bone
[15]. Consequently, the authors suggested that the skel-
etal loss occurring in hyperthyroidism was due to the
low TSH rather than thyroid hormone excess. In this
way, the receptor antibodies could play a direct role on
BMD by a similar mechanism to TSH, but the present
results seem to be opposite to those reported about ef-
fect of TSH on bone turnover. This difference could beFigure 3 Positive correlation between L2-L4- Z score and time
of evolution of the disease (months) in postmenopausal
patients with Graves’ disease (n = 27). (R = 0, 42, p < 0,032).
Figure 4 Negative correlation between TRAb (%) and time of
evolution of the disease (months) in pos-menopausal patients
with Graves’ disease (n = 27). (R = −0, 45, p < 0,02).
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bodies on the TSH receptor [36]; switches in the pool of
antibodies with predominance of blocking antibodies
that would not allow TSH action, which cannot be dis-
criminated with the TRAb assay performed in this study
[37] or regulation of the TSH receptor by stimulating
TSH autoantibodies [38]. In relation to TRAb on DMO,
the study by Majima et al. [16] is in line with our results.
They found that both higher serum TSH receptor anti-
bodies (TRAb) and thyroid stimulating antibodies
(TSAb) had a significant correlation with a reduction in
BMD at the distal radius in male patients with untreated
Graves’ disease. In addition, higher TSAb significantly
correlated with higher urinary N-terminal telopeptide of
type I collagen. On the other hand, Belsing et al. [39]
showed that the best predictors for BMD were a nega-
tive association with free T4 and a positive one with
TRAb. However, they included only premenopausal
women and the follow-up was shorter than in this study.
More recently, Morimura et al. [40] showed that TSH
positively regulated intracellular T3 production by con-
trolling type 2 iodothyronine deiodinase in human osteo-
blasts. It is, therefore, tempting to hypothesize that TSH
receptor antibodies might overproduce intracellular T3 to
decrease bone mass by accelerating bone turnover.
Previous studies have suggested that the past history
of Graves’ disease itself, not the current state of thyroid
function, is responsible for bone loss in women receiving
long-term levothyroxine therapy [17] indicating some
autoimmune effects of TRAb on bone metabolism. It is
known that normalization of the autoimmune abnormal-
ity comes much later than euthyroidism and the dis-
appearance of TRAb in serum came gradually over a
considerable period of time [41]. A decreased fracture
risk in patients with hyperthyroidism treated with sur-
gery and an increased fracture risk in patients treated
with radioiodine [31,42] could also support this hypoth-
esis of TRAb being involved in bone metabolism, con-
sidering that surgical treatment of Graves’ disease wasassociated with less pronounced or shorter elevation of
TRAb, whereas radioiodine treatment was associated
with a higher elevation [41].
It is not clear why the estrogen status influences thy-
roid hormones and TSH effects on bone mass. Both T3
and estradiol are essential for normal bone turnover
in vivo, as demonstrated by the skeletal phenotypes of
aromatase-deficient mice, human aromatase deficiency
and postmenopausal women [43]. One recent study
showed that acute TSH administration in postmeno-
pausal women resulted in an increase of serum N-
terminal propeptide of type-I procollagen, an index of
osteoblastic activity, associated with an increase of
serum RANKL. Lack of this response in premenopausal
women suggested an influence of estrogen status on
bone reactivity to TSH [44].
In our cross-sectional study, postmenopausal patients
with history of Graves’ disease hyperthyroidism, with
normal TSH and T4 and longstanding euthyroidism,
TRAb exhibited a significant negative correlation with
the Z-score of lumbar spine, suggesting that TRAb
might affect bone metabolism in these patients.
The present study has several limitations, such as the
small number of patients, the lack of BMD at the distal
radius measurement and the fact that there were no data
about bone status prior to the beginning of the disease,
but patients with other causes of BMD loss were ex-
cluded. The radioreceptor assay used to assess TRAb
concentrations in this study, based on inhibition of bind-
ing of 125I, could reflect stimulating as well as blocking
activities. Assays that detect cAMP production could be
useful to discriminate the antibodies activity [45,46].
The strengths include that it is the first study in
Graves’ disease patients with longstanding euthyroidism,
which has analyzed homogeneous subpopulations in
menopausal status and osteoporosis risk factors. These
results show, in relation to respective matched controls,
a normal BMD in premenopausal patients with previous
hyperthyroidism, but a diminished BMD in postmeno-
pausal patients with a previous history of perimeno-
pausal hyperthyroidism due to Graves’ disease, despite a
long time of euthyroidism. They also show, in the last
group of patients, an association between TRAb and
BMD regardless of hyperthyroidism. We consider that
these results suggest that the past history of Graves’ dis-
ease itself, and not the current state of thyroid function,
could be responsible for bone loss in postmenopausal
women.
This study does not show a direct causal relationship
nor does it elucidate the mechanisms by which serum
TRAb could affect bone measurements. Further studies
will be needed to understand the differential actions of
thyroid hormones, TSH and TRAb on osteoblasts and
osteoclasts and their relationship with estrogens.
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